Market Closed -
Japan Exchange
07:00:00 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
420
JPY
|
-0.71%
|
|
0.00%
|
-40.17%
|
Fiscal Period: January |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Capitalization
1 |
118,587
|
84,773
|
56,092
|
47,323
|
37,882
|
28,824
|
-
|
-
|
Enterprise Value (EV)
1 |
108,941
|
76,292
|
54,059
|
41,524
|
34,093
|
29,050
|
31,859
|
34,667
|
P/E ratio
|
-22.7
x
|
-25
x
|
-12
x
|
-7.75
x
|
-14
x
|
-8.56
x
|
-8.02
x
|
-9.77
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
265
x
|
-
|
-
|
-
|
-
|
-
|
43.7
x
|
10.2
x
|
EV / Revenue
|
244
x
|
-
|
-
|
-
|
-
|
-
|
48.3
x
|
12.2
x
|
EV / EBITDA
|
-20
x
|
-13.3
x
|
-8.33
x
|
-5.27
x
|
-7.53
x
|
-9.35
x
|
-9.19
x
|
-12.5
x
|
EV / FCF
|
-18.7
x
|
-73.7
x
|
-8.17
x
|
-5.58
x
|
-
|
-6.68
x
|
-6.87
x
|
-8.76
x
|
FCF Yield
|
-5.34%
|
-1.36%
|
-12.2%
|
-17.9%
|
-
|
-15%
|
-14.5%
|
-11.4%
|
Price to Book
|
11
x
|
10.4
x
|
32.8
x
|
12
x
|
14.9
x
|
-175
x
|
-9.52
x
|
-5.38
x
|
Nbr of stocks (in thousands)
|
51,785
|
51,785
|
51,793
|
63,606
|
66,929
|
68,630
|
-
|
-
|
Reference price
2 |
2,290
|
1,637
|
1,083
|
744.0
|
566.0
|
420.0
|
420.0
|
420.0
|
Announcement Date
|
16/03/20
|
17/03/21
|
11/03/22
|
16/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: January |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net sales
1 |
447.2
|
-
|
-
|
-
|
-
|
-
|
660
|
2,832
|
EBITDA
1 |
-5,446
|
-5,727
|
-6,488
|
-7,875
|
-4,525
|
-3,106
|
-3,468
|
-2,769
|
EBIT
1 |
-5,486
|
-5,802
|
-6,620
|
-7,899
|
-4,540
|
-4,040
|
-4,230
|
-3,470
|
Operating Margin
|
-1,226.69%
|
-
|
-
|
-
|
-
|
-
|
-640.97%
|
-122.56%
|
Earnings before Tax (EBT)
1 |
-5,157
|
-3,211
|
-4,560
|
-4,697
|
-2,542
|
-3,532
|
-3,621
|
-3,076
|
Net income
1 |
-5,158
|
-3,386
|
-4,677
|
-5,559
|
-2,644
|
-3,295
|
-3,528
|
-2,895
|
Net margin
|
-1,153.27%
|
-
|
-
|
-
|
-
|
-
|
-534.57%
|
-102.22%
|
EPS
2 |
-100.9
|
-65.38
|
-90.33
|
-95.99
|
-40.48
|
-49.07
|
-52.40
|
-42.98
|
Free Cash Flow
1 |
-5,813
|
-1,036
|
-6,613
|
-7,444
|
-
|
-4,352
|
-4,635
|
-3,958
|
FCF margin
|
-1,299.78%
|
-
|
-
|
-
|
-
|
-
|
-702.27%
|
-139.78%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
17/03/21
|
11/03/22
|
16/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: January |
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
---|
Net sales
|
19.46
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3,101
|
-2,570
|
-3,232
|
-3,052
|
-1,687
|
-1,844
|
-2,778
|
-4,622
|
-1,783
|
-1,494
|
-1,461
|
-1,623
|
-3,085
|
-640.3
|
-813.7
|
-
|
Operating Margin
|
-15,936.2%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-3,109
|
-3,205
|
-6
|
-2,127
|
-886
|
869
|
-
|
-774
|
1,211
|
-
|
-866
|
-
|
-1,858
|
116
|
-
|
-
|
Net income
|
-3,109
|
-3,207
|
-178.9
|
-2,134
|
-981
|
-315
|
-
|
-2,154
|
396
|
-
|
-626.2
|
-
|
-1,787
|
-96
|
-
|
-
|
Net margin
|
-15,977.31%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-61.94
|
-
|
-41.21
|
-18.95
|
-5.980
|
-
|
-39.26
|
8.140
|
-
|
-9.680
|
-
|
-27.59
|
-1.400
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
14/09/20
|
17/03/21
|
14/09/21
|
15/12/21
|
14/06/22
|
14/09/22
|
14/09/22
|
15/12/22
|
16/03/23
|
14/06/23
|
14/09/23
|
14/09/23
|
14/12/23
|
18/03/24
|
18/03/24
|
Fiscal Period: January |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
226
|
3,034
|
5,843
|
Net Cash position
1 |
9,646
|
8,480
|
2,033
|
5,799
|
3,789
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.0728
x
|
-0.8748
x
|
-2.11
x
|
Free Cash Flow
1 |
-5,813
|
-1,036
|
-6,613
|
-7,444
|
-
|
-4,352
|
-4,635
|
-3,958
|
ROE (net income / shareholders' equity)
|
-52.4%
|
-35.7%
|
-95.1%
|
-195%
|
-80.5%
|
-191%
|
-958%
|
-
|
ROA (Net income/ Total Assets)
|
-34.8%
|
-45.1%
|
-48.6%
|
-74.8%
|
-46.7%
|
-66.4%
|
-
|
-
|
Assets
1 |
14,824
|
7,505
|
9,628
|
7,428
|
5,661
|
4,963
|
-
|
-
|
Book Value Per Share
2 |
209.0
|
157.0
|
33.00
|
62.10
|
38.10
|
-2.400
|
-44.10
|
-78.00
|
Cash Flow per Share
2 |
-100.0
|
-63.90
|
-87.80
|
-95.60
|
-40.30
|
-44.80
|
-39.10
|
-21.30
|
Capex
1 |
95.7
|
96.2
|
47
|
9
|
-
|
310
|
360
|
410
|
Capex / Sales
|
21.39%
|
-
|
-
|
-
|
-
|
-
|
54.55%
|
14.48%
|
Announcement Date
|
16/03/20
|
17/03/21
|
11/03/22
|
16/03/23
|
18/03/24
|
-
|
-
|
-
|
Average target price
800
JPY Spread / Average Target +90.48% Consensus |
1st Jan change
|
Capi.
|
---|
| -40.17% | 187M | | +2.91% | 108B | | +10.26% | 105B | | +1.57% | 23.46B | | -12.22% | 21.72B | | -7.05% | 18.64B | | -37.64% | 17.45B | | -6.74% | 17.19B | | +6.38% | 13.99B | | +36.81% | 12.53B |
Bio Therapeutic Drugs
|